AwesomeCapital
Search This Blog
Thursday, September 7, 2023
KalVista Operational Update
Sebetralstat Phase 3 KONFIDENT Clinical Trial Achieves Target Enrollment; Data Readout on Track for Q4
Preparations Continue for NDA filing H1 2024 and Rapid Commercialization Upon Approval
https://www.biospace.com/article/releases/kalvista-pharmaceuticals-reports-first-fiscal-quarter-results-and-provides-operational-update/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.